Press Releases

BioIVT to Host Emerging Technologies in Diagnostics Symposium

Advances include a rapid vaccine analysis platform, companion diagnostic for solid tumors, and bioanalytical validation methods for biomarkers and companion diagnostics

Shimmer Solicits Clinical Research Community Input on Expanded Open Wearables Initiative (OWEAR) Vision

As OWEAR embarks on its second year, organizers see potential to expand its positive industry impact beyond the organization’s original mission

Protheragen Offers License Opportunities for Drug Development Programs

Protheragen, a company founded in Ronkonkoma, New York, 2009, announces to offer license opportunities for drug R&D companies.

AI & Medicine Announces Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling for Drug Discovery

On October 24, 2020, AI & Medicine, one of the forerunners in the AI-assisted medicine area, announces it now provides PK/PD modeling service to help scientists and researchers more efficiently screen drugs and thus accelerating the process of new drug development. The company is known as an expert in applying artificial intelligence into drug discovery, personalized healthcare and various other medical applications.

Alfa Chemistry Offers Fluorinated Building Blocks for Material, Medicinal, Agricultural, Organic Chemistry Research

The benefits of fluorochemistry to pharmaceutical applications are obvious and the past decades has seen increasing synthesis of fluorinated compounds in the preparation of new pharmaceuticals and agrochemicals. To better meet the growing needs of customers worldwide, the New York-based chemical supplier Alfa Chemistry announced to offer high-purity fluorinated building blocks for various application scenarios such as material, medicine, agriculture and organic chemistry.

Notable Labs Announces Partnership With All4Cure

Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, and All4Cure, which has built a real world data powered network of patients, clinicians and researchers to dramatically improve outcomes for millions of patients with cancer, today announced their partnership. Notable will leverage All4Cure’s network to enhance and expand its functional precision oncology platform.

Matexcel Released a Series of Collagen Products for Worldwide Researchers

 Flow Cytometry Analysis in Plants Now Available at Lifeasible

WCG Appoints Two New Independent Directors to its Board

Dr. Kavita Patel and Ms. Pascale Witz bring global healthcare policy and pharmaceutical executive experience to WCG

IntegrateRNA miRNA Services: Powerful Support for miRNA Basic Research, Biomarker Discovery and Preclinical Trials

Plant Extracts at Alfa Chemistry Serve as Materials for Cosmetics, Health Food, and Medical Care

Notable Labs Enters Into Partnership With myTomorrows

Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.

SB3000 the life science technology company establishes its HQ in Copenhagen

Swedish Biomimetics 3000 Ltd, a life science technology company which has developed a world leading green technology platform used in the continuous manufacturing of pharmaceuticals, has established a new head office and scientific research facilities in Copenhagen. The company, which is called Swedish Biomimetics 3000 ApS, believes that it will benefit from the sector specific expertise in Denmark in expanding its capabilities. Going forward, the company will have key operations in both the UK and Denmark.

Phosphine Ligands Now Accessible at Alfa Chemistry Catalysts

Alfa Chemistry Catalysts, a specialized branch of Alfa Chemistry, announced to offer wide-ranged phosphine ligands which are extensively used in petrochemical industry, pharmaceutical industry, organic synthesis, analysis and other areas.

AI & Medicine's Drug Research and Development Platform Assists Biomarker Discovery

AI & Medicine, one of the forerunners in AI-assisted drug research and development, announced that its platform can significantly facilitate biomarker discovery, which is traditionally a very time-consuming and resource-intensive process.

Shimmer to Highlight Its Verisense Wearable Sensing Platform for Clinical Trials and OWEAR, the Open Wearables Initiative, at the DPHARM Virtual Conference

The Verisense platform was built from the ground up to monitor clinical trial participants’ activity and sleep levels remotely. It was developed to satisfy the needs of, and place minimum burden on, all the stakeholders – sponsors, clinical research organizations (CROs), trial sites, and participants. OWEAR is an industry collaboration, which is developing a database of open source software and datasets, together with validation papers, for wearable sensors and other connected health technologies at www.owear.org.

Europital launches as a science-driven full service CRO

Expanded CRO services to support biotechs and mid-sized pharma companies across trials in more than 40 countries

VivaLNK Supports Large Scale Atrial Fibrillation Study of Wearable ECG Sensors

Multi-year, 3,000 subjects study aims to detect biomarkers of early atrial transformation in atrial fibrillation

PHARMASEAL’s £1million crowdfunding campaign aimed at increasing clinical trial turnaround times gains momentum

A £1 million crowdfunding campaign launched by PHARMASEAL to revolutionise global clinical trials and vaccine development has reached the next campaign milestone. Launched by the new provider of clinical trial management and governance solutions last month, the campaign is aimed at raising capital in order to continue its journey using next-generation technology to improve the efficiency of clinical trials on a worldwide scale.

Raremark® implement a new, dynamic executive team to drive patient-centric drug development in rare diseases

Following accelerated levels of growth over the last six months, Raremark®, the leading rare disease patient network and real-world insights provider has reasserted its commitment to patient-centric drug development by implementing a new, dynamic executive team to drive the commercial vision and future growth of the company.